KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Debt (2016 - 2025)

Sarepta Therapeutics has reported Total Debt over the past 15 years, most recently at $829.0 million for Q4 2025.

  • Quarterly results put Total Debt at $829.0 million for Q4 2025, down 27.1% from a year ago — trailing twelve months through Dec 2025 was $829.0 million (down 27.1% YoY), and the annual figure for FY2025 was $829.0 million, down 27.1%.
  • Total Debt for Q4 2025 was $829.0 million at Sarepta Therapeutics, down from $1.1 billion in the prior quarter.
  • Over the last five years, Total Debt for SRPT hit a ceiling of $1.5 billion in Q4 2022 and a floor of $829.0 million in Q4 2025.
  • Median Total Debt over the past 5 years was $1.1 billion (2025), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Total Debt: surged 58.6% in 2021 and later dropped 27.1% in 2025.
  • Sarepta Therapeutics' Total Debt stood at $1.1 billion in 2021, then soared by 40.79% to $1.5 billion in 2022, then dropped by 19.83% to $1.2 billion in 2023, then dropped by 8.15% to $1.1 billion in 2024, then fell by 27.1% to $829.0 million in 2025.
  • The last three reported values for Total Debt were $829.0 million (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.